WO2018210354A1 - 一种抗痛风药Lesinurad的新型制备方法及其关键中间体 - Google Patents
一种抗痛风药Lesinurad的新型制备方法及其关键中间体 Download PDFInfo
- Publication number
- WO2018210354A1 WO2018210354A1 PCT/CN2018/095269 CN2018095269W WO2018210354A1 WO 2018210354 A1 WO2018210354 A1 WO 2018210354A1 CN 2018095269 W CN2018095269 W CN 2018095269W WO 2018210354 A1 WO2018210354 A1 WO 2018210354A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- group
- formula
- reaction
- lesinurad
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 39
- 229960003838 lesinurad Drugs 0.000 title claims abstract description 24
- FGQFOYHRJSUHMR-UHFFFAOYSA-N lesinurad Chemical compound OC(=O)CSC1=NN=C(Br)N1C(C1=CC=CC=C11)=CC=C1C1CC1 FGQFOYHRJSUHMR-UHFFFAOYSA-N 0.000 title claims abstract description 22
- 229960002708 antigout preparations Drugs 0.000 title abstract description 4
- 150000001875 compounds Chemical class 0.000 claims abstract description 61
- 238000006243 chemical reaction Methods 0.000 claims abstract description 56
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical group CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims abstract description 48
- 238000000034 method Methods 0.000 claims abstract description 20
- 239000000203 mixture Substances 0.000 claims abstract description 19
- 239000002904 solvent Substances 0.000 claims abstract description 18
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims abstract description 15
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 13
- 150000002367 halogens Chemical class 0.000 claims abstract description 12
- 230000008569 process Effects 0.000 claims abstract description 8
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical group CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims abstract description 7
- 125000002827 triflate group Chemical group FC(S(=O)(=O)O*)(F)F 0.000 claims abstract description 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims abstract description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims abstract description 3
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims abstract description 3
- KXKVLQRXCPHEJC-UHFFFAOYSA-N methyl acetate Chemical group COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 claims abstract 2
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 30
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 24
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 18
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 17
- -1 Lesinurad intermediate compound Chemical class 0.000 claims description 12
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims description 12
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 12
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 10
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 10
- 229940126214 compound 3 Drugs 0.000 claims description 10
- 238000000746 purification Methods 0.000 claims description 10
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 9
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 9
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 claims description 8
- 238000005893 bromination reaction Methods 0.000 claims description 7
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 claims description 6
- 238000006460 hydrolysis reaction Methods 0.000 claims description 6
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 6
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical group CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 6
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims description 5
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 5
- MKIJJIMOAABWGF-UHFFFAOYSA-N methyl 2-sulfanylacetate Chemical compound COC(=O)CS MKIJJIMOAABWGF-UHFFFAOYSA-N 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 5
- VSTXCZGEEVFJES-UHFFFAOYSA-N 1-cycloundecyl-1,5-diazacycloundec-5-ene Chemical compound C1CCCCCC(CCCC1)N1CCCCCC=NCCC1 VSTXCZGEEVFJES-UHFFFAOYSA-N 0.000 claims description 4
- 239000003153 chemical reaction reagent Substances 0.000 claims description 4
- QABLOFMHHSOFRJ-UHFFFAOYSA-N methyl 2-chloroacetate Chemical compound COC(=O)CCl QABLOFMHHSOFRJ-UHFFFAOYSA-N 0.000 claims description 4
- 239000005051 trimethylchlorosilane Substances 0.000 claims description 4
- MENYRYNFSIBDQN-UHFFFAOYSA-N 5,5-dibromoimidazolidine-2,4-dione Chemical compound BrC1(Br)NC(=O)NC1=O MENYRYNFSIBDQN-UHFFFAOYSA-N 0.000 claims description 3
- 230000031709 bromination Effects 0.000 claims description 3
- IYYIVELXUANFED-UHFFFAOYSA-N bromo(trimethyl)silane Chemical compound C[Si](C)(C)Br IYYIVELXUANFED-UHFFFAOYSA-N 0.000 claims description 3
- HHBCEKAWSILOOP-UHFFFAOYSA-N 1,3-dibromo-1,3,5-triazinane-2,4,6-trione Chemical compound BrN1C(=O)NC(=O)N(Br)C1=O HHBCEKAWSILOOP-UHFFFAOYSA-N 0.000 claims description 2
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 claims description 2
- AMATXUCYHHHHHB-UHFFFAOYSA-N 5,5-dibromo-1,3-diazinane-2,4,6-trione Chemical compound BrC1(Br)C(=O)NC(=O)NC1=O AMATXUCYHHHHHB-UHFFFAOYSA-N 0.000 claims description 2
- 229940125898 compound 5 Drugs 0.000 claims description 2
- JGJLWPGRMCADHB-UHFFFAOYSA-N hypobromite Inorganic materials Br[O-] JGJLWPGRMCADHB-UHFFFAOYSA-N 0.000 claims description 2
- CSRZQMIRAZTJOY-UHFFFAOYSA-N trimethylsilyl iodide Chemical compound C[Si](C)(C)I CSRZQMIRAZTJOY-UHFFFAOYSA-N 0.000 claims description 2
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 claims 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 claims 1
- 229940050176 methyl chloride Drugs 0.000 claims 1
- QGJOPFRUJISHPQ-UHFFFAOYSA-N Carbon disulfide Chemical compound S=C=S QGJOPFRUJISHPQ-UHFFFAOYSA-N 0.000 abstract description 8
- 231100000331 toxic Toxicity 0.000 abstract description 6
- 230000002588 toxic effect Effects 0.000 abstract description 6
- 238000006467 substitution reaction Methods 0.000 abstract description 3
- 230000015572 biosynthetic process Effects 0.000 abstract description 2
- 238000003786 synthesis reaction Methods 0.000 abstract description 2
- ZWZVWGITAAIFPS-UHFFFAOYSA-N thiophosgene Chemical compound ClC(Cl)=S ZWZVWGITAAIFPS-UHFFFAOYSA-N 0.000 abstract description 2
- 239000003513 alkali Substances 0.000 abstract 2
- 230000007613 environmental effect Effects 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 1
- 238000000926 separation method Methods 0.000 abstract 1
- 125000005490 tosylate group Chemical group 0.000 abstract 1
- 235000019439 ethyl acetate Nutrition 0.000 description 17
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 12
- 239000012074 organic phase Substances 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 239000007858 starting material Substances 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 229940125782 compound 2 Drugs 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
- NYKSBMRQNSCVMO-UHFFFAOYSA-N 4-cyclopropylnaphthalen-1-amine Chemical compound C12=CC=CC=C2C(N)=CC=C1C1CC1 NYKSBMRQNSCVMO-UHFFFAOYSA-N 0.000 description 3
- 201000005569 Gout Diseases 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- OVPHARXTEGNOCQ-UHFFFAOYSA-N [S].ClC(Cl)=O Chemical compound [S].ClC(Cl)=O OVPHARXTEGNOCQ-UHFFFAOYSA-N 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- AQEFLFZSWDEAIP-UHFFFAOYSA-N di-tert-butyl ether Chemical compound CC(C)(C)OC(C)(C)C AQEFLFZSWDEAIP-UHFFFAOYSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000012065 filter cake Substances 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000009776 industrial production Methods 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- 235000011152 sodium sulphate Nutrition 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- 101000821902 Homo sapiens Solute carrier family 22 member 11 Proteins 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- 201000001431 Hyperuricemia Diseases 0.000 description 2
- 108091006745 SLC22A12 Proteins 0.000 description 2
- 102100021493 Solute carrier family 22 member 11 Human genes 0.000 description 2
- 102100021495 Solute carrier family 22 member 12 Human genes 0.000 description 2
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 2
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- NAFSTSRULRIERK-UHFFFAOYSA-M monosodium urate Chemical group [Na+].N1C([O-])=NC(=O)C2=C1NC(=O)N2 NAFSTSRULRIERK-UHFFFAOYSA-M 0.000 description 2
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 229940116269 uric acid Drugs 0.000 description 2
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 1
- ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 2,3-dimethylbutane Chemical group CC(C)C(C)C ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 description 1
- 238000003747 Grignard reaction Methods 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 102100030935 Solute carrier family 2, facilitated glucose transporter member 9 Human genes 0.000 description 1
- 108010093894 Xanthine oxidase Proteins 0.000 description 1
- 102100033220 Xanthine oxidase Human genes 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- QGJOPFRUJISHPQ-NJFSPNSNSA-N carbon disulfide-14c Chemical compound S=[14C]=S QGJOPFRUJISHPQ-NJFSPNSNSA-N 0.000 description 1
- FOCAUTSVDIKZOP-UHFFFAOYSA-M chloroacetate Chemical compound [O-]C(=O)CCl FOCAUTSVDIKZOP-UHFFFAOYSA-M 0.000 description 1
- 229940089960 chloroacetate Drugs 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 description 1
- VEUUMBGHMNQHGO-UHFFFAOYSA-N ethyl chloroacetate Chemical compound CCOC(=O)CCl VEUUMBGHMNQHGO-UHFFFAOYSA-N 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- COTUIISAXUDHPP-UHFFFAOYSA-N methyl 2-[[4-(4-cyclopropylnaphthalen-1-yl)-1,2,4-triazol-3-yl]sulfanyl]acetate Chemical compound COC(=O)CSC1=NN=CN1C(C1=CC=CC=C11)=CC=C1C1CC1 COTUIISAXUDHPP-UHFFFAOYSA-N 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- JDEJGVSZUIJWBM-UHFFFAOYSA-N n,n,2-trimethylaniline Chemical compound CN(C)C1=CC=CC=C1C JDEJGVSZUIJWBM-UHFFFAOYSA-N 0.000 description 1
- XHRLHFIZYKNVGV-UHFFFAOYSA-N n-amino-n-formylformamide Chemical compound O=CN(N)C=O XHRLHFIZYKNVGV-UHFFFAOYSA-N 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 150000003852 triazoles Chemical group 0.000 description 1
- 108010078530 urate transporter Proteins 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D249/12—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Definitions
- the invention relates to the technical field of drug synthesis, in particular to a novel preparation method of an anti-gout drug Lesinurad and a key intermediate thereof.
- Gout is a crystal-associated joint disease caused by deposition of monosodium urate (MSU), which is directly related to hyperuricemia caused by a disorder of sputum metabolism and/or a decrease in uric acid excretion. More than 20 million patients worldwide have gout. Lesinurad is an oral SLC22A12 inhibitor, and SLC22A12 is also known as urate transporter 1 (URAT1) and organic anion transporter 4 (OAT4).
- URAT1 urate transporter 1
- OAT4 organic anion transporter 4
- EMA European Medicines Agency
- the route is the patent route of the compound reported by the original researcher.
- the reaction step is lengthy and the compound D is used as the starting material.
- the total yield is about 25.8%, and the route uses highly toxic phosgene, which is environmentally friendly and healthy. Safety has a certain impact.
- the route is a patent for the preparation of the original researcher, and the total yield is good, but the highly toxic sulfur phosgene is used in the route.
- the route avoids the use of sulphur phosgene which is harmful to the environment, health and safety, it has the disadvantages that the starting materials used are not easy to obtain, the price is high, and the total yield is only about 25%.
- This route is similar to the original route of the manufacturer's preparation route.
- the sulfhydryl triazole ring is obtained by cyclization of different hydrazine reagents, and then the bromine is hydrolyzed to obtain Lesinurad.
- the method has a long reaction step and a highly toxic carbon disulfide is used in the route.
- the process requires column purification in the bromination step, which is complicated in operation and is not suitable for industrial production.
- a comprehensive analysis of the existing Lesinurad preparation method reveals that most of the bromine on the Lesinurad structure is converted by amino groups. This step is complicated in operation and the raw materials or reagents used are expensive and the production cost is high. In addition, most of the existing preparation methods use highly toxic sulfur phosgene or carbon disulfide, which causes many disadvantages in the safety, economical and large-scale production of the reaction.
- the technical problem to be solved by the present invention is to overcome the deficiencies of the prior art, and to provide a novel preparation method of Lesinurad and a new intermediate, which is more economical, more efficient, safer, more environmentally friendly, and suitable for large-scale industrial production. Synthetic process.
- the method comprises the steps of: subjecting a compound of formula II to R 3 -SH in the presence of a first solvent and a first base to form a mixture comprising a compound of formula III and a compound of formula IV; and adding a second base to the resulting mixture And reacting with R 3 X to obtain a compound of formula III;
- R represents a cyclopropyl group, a halogen, a triflate group, a mesylate group, a p-toluenesulfonate group, preferably, R represents a cyclopropane group;
- R 3 represents -COCH 3 , benzyl or -CH 2 R 4 , wherein R 4 represents an ester group, -C(O)OC 2 H 5 , -C(O)OCH 3 , -CN, -CH 2 OH or a phenyl group substituted with one or more of a C1-C6 alkyl group; a halogen;
- X represents a halogen
- the first solvent is selected from one of N,N-dimethylformamide, N-methylpyrrolidone or acetonitrile or any combination thereof.
- the first base and the second base in the step 1) and the step 2) are respectively selected from 1,8-diazabicycloundec-7-ene and diisopropyl. Either one of ethylethylamine, triethylamine, potassium carbonate or sodium carbonate or any combination thereof.
- the first base and the second base may be the same or different.
- the mixture obtained in the step 1) can be directly converted into the compound III without further purification.
- the inventors have found through research that in the preparation of lesinurad, the substitution reaction of the compound of the formula II with R 3 -SH in the presence of the first solvent and the first base inevitably results in a mixture containing the compound of the formula III and the compound of the formula IV, wherein III compound accounts for about 50%, and compound IV accounts for about 30%. If the compound of formula IV is directly removed as impurities, the yield will be low and the cost will be affected; if a large amount of the compound of formula III containing a large amount of the compound of formula IV is directly The next hydrolysis reaction results in a large content of the impurities in the crude product of the final product, which is difficult to purify.
- the compound of the formula III and the compound of the formula IV have little difference in polarity, and the content in the mixture is not much different, and it is difficult to separate by crystallization or beating.
- Inventors have surprisingly found that with R 3 X after treatment, almost all of the compounds of formula IV are converted to compounds of formulas III, greatly improving the product yield of the compound of formulas III, can be carried out without purification and subsequent reaction directly, eventually generating Lesinurad.
- a compound of formula III when R is cyclopropyl, a compound of formula III may be in the conversion reaction of R 3 through a further group, such as hydrolysis reaction, the compound of formula III is converted into Lesinurad.
- R represents a halogen, a triflate group, a mesylate group or a p-toluenesulfonate group
- R when it represents a halogen, a triflate group, a mesylate group or a p-toluenesulfonate group, it may be subjected to a Grignard reaction or a hydrolysis first. a reaction, or other conventional chemical reaction, to convert R to a cyclopropane group;
- the reaction of converting R into a cyclopropyl group and the group converting reaction by R 3 have no special requirements, and the former may be carried out first, and may be carried out first.
- the present invention provides a Lesinurad intermediate compound of the formula I and formula II, the structural formula of which is as follows:
- R represents a cyclopropane group, a halogen, a triflate group, a mesylate group or a p-toluenesulfonate group; preferably, R represents a cyclopropane group; in some embodiments of the invention,
- the compounds of formula I and formula II are more specifically compounds 2 and 3 of the formula:
- Another technical solution adopted by the present invention is a method for preparing a Lesinurad intermediate compound of the general formula II, which comprises subjecting a compound of the formula I to a bromination reaction in a second solvent to form a compound of the formula II, and the reaction is as follows :
- the bromination reagent used in the bromination reaction is selected from the group consisting of liquid bromine, bromine water, N-bromosuccinimide, dibromohydantoin, phenyltrimethyltribromide. Or one or any combination of ammonium, 5,5-dibromobarbituric acid or dibromoisocyanuric acid;
- the second solvent is selected from the group consisting of tetrahydrofuran, 2-methyltetrahydrofuran, dichloromethane or acetonitrile One or any combination thereof.
- the Lesinurad intermediate compound of the formula I can be reacted by reacting a compound of the formula V or a salt thereof and N,N-diformylhydrazine in a third solvent in the presence of a trimethylhalosilane and a third base.
- the compound of formula I is produced and the reaction is as follows:
- R represents a cyclopropane group, a halogen, a triflate group, a mesylate group or a p-toluenesulfonate group; preferably, R represents a cyclopropane group.
- the third solvent described in the preparation method provided by the present invention is selected from one or a combination of pyridine, acetonitrile or toluene; and the third base is selected from the group consisting of pyridine, triethylamine or diisopropylethylamine ( One or any combination of DIPEA); the trimethylhalosilane is selected from one of trimethylchlorosilane, trimethylbromosilane, or trimethyliodosilane, or any combination thereof.
- the invention adopts a more specific technical scheme: a preparation method of a Lesinurad compound, and the preparation steps are as follows:
- the method comprises: subjecting compound 3 to methyl thioglycolate in a substitution reaction in the presence of a first solvent and a first base to form a mixture containing compound 4 and compound 5; and adding a second base and a chloroacetate to the obtained mixture
- the ester is reacted to give compound 4; compound 4 is further converted to lesinurad, compound 6; preferably, compound 4 obtained in step 2) is directly converted to lesinurad by further hydrolysis without further purification.
- the first solvent is selected from one of N,N-dimethylformamide, N-methylpyrrolidone or acetonitrile or any combination thereof; the first of the steps 1) and 2)
- the base and the second base are respectively selected from one of 1,8-diazabicycloundec-7-ene, diisopropylethylamine, triethylamine, potassium carbonate or sodium carbonate or any combination thereof .
- a new lesinurad intermediate and a novel preparation method thereof are provided, which makes it possible to avoid the use of highly toxic and difficult-to-operate thiophosgene and a process for damaging nerve and vascular poison carbon disulfide.
- reaction yield is high. Compared with other routes in the prior art, the reaction yield can be increased from about 25% to about 44%.
- the preparation method of Lesinurad can be expressed by the reaction equation as follows:
- Example 7A Preparation of methyl 4-(4-cyclopropylnaphthalene)-3-thioacetate-5-bromo-1,2,4-triazole
- Example 7B Preparation of methyl 4-(4-cyclopropylnaphthalene)-3-thioacetate-5-bromo-1,2,4-triazole
- reaction mixture was diluted with ethyl acetate.
- the organic phase was washed once with 0.5N aqueous hydrochloric acid, and then washed three times with water, and dried to give a crude compound of compound 4 which was used for the next step without purification.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
提供了一种抗痛风药Lesinurad的新型制备方法及其关键中间体;其中,该方法包括以下反应步骤:1)将式II化合物与R 3-SH在第一溶剂和第一碱存在下发生取代反应,生成含有式III化合物和式IV化合物的混合物;2)在得到的混合物中加第二碱及R 3X进行反应,得到式III化合物;其中,R代表环丙烷基、卤素、三氟甲磺酸酯基、甲磺酸酯基或对甲苯磺酸酯基;优选地,R代表环丙烷基;R 3代表-COCH 3、苄基或-CH 2R 4,其中R 4代表乙酸甲酯基、乙酸乙酯基、-C(O)OC 2H 5、-C(O)OCH 3、-CN、-CH 2OH或被选自C1~C6烷基、卤素中的一种或多种取代的苯基;X代表卤素。所提供的工艺可将式IV化合物不经分离直接转化为产物式III化合物,大大提高了反应的收率和简化了操作步骤。所提供的新中间体的合成不需要用到高毒性的硫光气和二硫化碳,大大提高了工艺的安全和环保性。
Description
本申请要求于2017年5月17日提交中国专利局、申请号为201710346180.2发明名称为“一种抗痛风药Lesinurad的新型制备方法及其关键中间体”的中国专利申请的优先权,其全部内容通过引用结合在本申请中。
本发明涉及药物合成技术领域,尤其涉及一种抗痛风药Lesinurad的新型制备方法及其关键中间体。
痛风是由单钠尿酸盐(MSU)沉积所致的晶体相关性关节病,与嘌呤代谢紊乱和/或尿酸排泄减少所致的高尿酸血症直接相关。全球痛风患者高达2000多万。Lesinurad是一款口服的SLC22A12抑制剂,SLC22A12也被称为尿酸盐转运体1(URAT1)和有机阴离子转运蛋白4(OAT4)。2015年12月欧洲药品管理局(EMA)批准阿斯利康的药物Lesinurad与另一种降低体内尿酸生成的黄嘌呤氧化酶抑制剂联用作为与痛风关联高尿酸血症的治疗。
以下文献报道了Lesinurad化合物的合成路线:
(1)专利WO2006026356报道的合成路线如下:
该路线为原研厂家报道的化合物专利路线,反应步骤冗长,以化合物D为起始物料来计算,总收率为25.8%左右,且路线中使用了高毒性的硫光气,对环境,健康和安全有一定的影响。
(2)专利WO2014008295报道的合成路线如下:
该路线为原研厂家的制备专利,总收率较好,但路线中使用高毒性的硫光气。
(3)中国专利CN102040546报道的合成路线如下
该路线虽然避免使用对环境,健康及安全有害的硫光气,但具有所使用的起始原料不易得,价格昂贵,且总收率也只有25%左右等缺点。
(4)中国专利CN103524440报道的合成路线如下:
该路线和原研厂家的制备路线所用思路类似,都是通过不同的联肼类试剂环合得到巯基三氮唑环,然后上溴再水解得到Lesinurad。但该方法反应步骤长,且路线中使用了高毒性的二硫化碳,该工艺在溴化步骤中需要过柱纯化,操作复杂,不适合工业化生产。
综合分析现有的Lesinurad制备方法可知,发现Lesinurad结构上的溴大多是通过氨基转化而来,该步骤操作复杂且所用原料或试剂价格昂贵,生产成本高。另外现有的制备方法大多用到高毒性的硫光气或二硫化碳,从而造成这些路线在反应操作安全性,经济性以及规模化生产上存在诸多不利因素。
发明内容
本发明所要解决的技术问题是克服现有技术的不足,提供一种Lesinurad的新型制备方法以及新的中间体,该制备方法更经济、更高效、更安全、更环保、适于大规模工业化生产的合成工艺。
本发明通过以下技术方案实现:一种通式III的Lesinurad中间体化合物的制备方法,具体合成路线如下:
该方法步骤包括:将式II化合物与R
3-SH在第一溶剂和第一碱存在下发生取代反应,生成含有式III化合物和式IV化合物的混合物;再在得到的混合物中加第二碱及R
3X进行反应,得到式III化合物;
其中,R代表环丙烷基、卤素、三氟甲磺酸酯基、甲磺酸酯基、对甲苯磺酸酯基,优选地,R代表环丙烷基;
R
3代表-COCH
3、苄基或-CH
2R
4,其中R
4代表酯基,-C(O)OC
2H
5、-C(O)OCH
3、-CN、-CH
2OH或被选自C1~C6烷基、卤素中的一种或多种取代的苯基;
X代表卤素。
根据本发明提供的制备方法,所述的第一溶剂选自N,N-二甲基甲酰胺、N-甲基吡咯烷酮或乙腈中的一种或其任意组合。
根据本发明提供的制备方法,所述的步骤1)和步骤2)中的第一碱、第二碱分别选自1,8-二氮杂二环十一碳-7-烯、二异丙基乙基胺、三乙胺、碳酸钾或碳酸钠中的一种或其任意组合。所述第一碱和第二碱可以相同或不同。
根据本发明提供的制备方法,所述步骤1)得到的混合物可以不纯化直接进行下一步反应转化成化合物III。
发明人通过研究发现,在制备lesinurad时,将式II化合物与R
3-SH在第一溶剂和第一碱存在下发生取代反应,必然会生成含有式III化合物和式IV化合物的混合物,其中式III化合物占50%左右,式IV化合物占30%左右,如果将式IV化合物直接当杂质除去的话,会造成收率变低,影响成本;若将含有大量的式IV化合物的粗品式III化合物直接进行下一步水解反应,会导致最终产物粗品中该杂质含量较大,难以纯化。另外,式III化合物和式IV化合物极性差别不大,且混合物中含量相差不大,不易通过结晶或打浆分离。发明人惊奇的发现用R
3X处理后,几乎所有的式IV化合物都转化为式III化合物,大大提高了产物式III化合物的收率,且不用纯化可直接进行下后续反应,最终生成Lesinurad。
在本发明的一些具体实施方式中,当R为环丙烷基时,可以使式III化合物中的R
3通过进一步的基团转化反应,例如水解反应,将式III化合物转化成 Lesinurad。
在本发明的另一些具体实施方式中,当R代表卤素、三氟甲磺酸酯基、甲磺酸酯基或对甲苯磺酸酯基时,可以通过格氏反应,或先水解后格氏反应,或其他常规的化学反应,将R转化成环丙烷基;
并通过使式III化合物中的R
3通过进一步的基团转化反应,例如水解反应,最终将式III化合物转化成Lesinurad;
需要说明的是,在此具体实施方式中,R转化成环丙烷基的反应与R
3进行的基团转化反应,二者之间的先后顺序没有特殊要求,可以先进行前者,可以先进行后者。本发明另一方面提供了一种通式I和通式II的Lesinurad中间体化合物,其结构式如下所示:
其中,R代表环丙烷基、卤素、三氟甲磺酸酯基、甲磺酸酯基或对甲苯磺酸酯基;优选地,R代表环丙烷基;在本发明的一些实施方式中,通式I和通式II化合物更具体地为下式化合物2和化合物3:
本发明采用的又一技术方案为:一种通式II的Lesinurad中间体化合物的制备方法,该方法包括使式I化合物在第二溶剂中发生溴代反应,生成式II 化合物,反应如下所示:
根据本发明提供的制备方法,所述的溴化反应采用的溴化试剂选自液溴、溴水、N-溴代丁二酰亚胺、二溴海因、苯基三甲基三溴化铵、5,5-二溴巴比妥酸或二溴异氰尿酸中的一种或其任意组合;所述的第二溶剂选自四氢呋喃、2-甲基四氢呋喃、二氯甲烷或乙腈中的一种或其任意组合。
所述的通式I的Lesinurad中间体化合物可以通过使式V化合物或其盐和N,N-二甲酰肼在第三溶剂中,在三甲基卤硅烷以及第三碱的存在下反应,生成式I化合物,反应如下所示:
其中,R代表环丙烷基、卤素、三氟甲磺酸酯基、甲磺酸酯基或对甲苯磺酸酯基;优选地,R代表环丙烷基。
根据本发明提供的制备方法所述的第三溶剂选自吡啶、乙腈或甲苯中的一种或其组合;所述的第三碱选自吡啶、三乙胺或者二异丙基乙基胺(DIPEA)中的一种或其任意组合;所述的三甲基卤硅烷选自三甲基氯硅烷、三甲基溴硅烷或三甲基碘硅烷中的一种或其任意组合。
本发明采用更具体的技术方案为:一种Lesinurad化合物的制备方法,制 备步骤如下:
该方法包括:将化合物3与巯基乙酸甲酯在第一溶剂和第一碱存在下发生取代反应,生成含有化合物4和化合物5的混合物;再在得到的混合物中加第二碱及氯乙酸甲酯进行反应,得到化合物4;化合物4再进一步转化成lesinurad,即化合物6;优选地所述步骤2)得到的化合物4不纯化直接进行下一步水解反应转化成lesinurad。
其中,所述的第一溶剂选自N,N-二甲基甲酰胺、N-甲基吡咯烷酮或乙腈中的一种或其任意组合;所述的步骤1)和步骤2)中的第一碱、第二碱分别选自1,8-二氮杂二环十一碳-7-烯、二异丙基乙基胺、三乙胺、碳酸钾或碳酸钠中的一种或其任意组合。
与现有技术相比,本发明提供的技术方案具有如下有益的技术效果:
(1)提供了一种新的lesinurad中间体及其新的制备方法,使避免使用高毒性且不易操作的硫光气以及损害神经和血管毒物二硫化碳的工艺成为可能。
(2)提供了一种lesinurad高效的制备方法,该方法有利于质量控制,转化率高,生产成本低。
(3)根据本发明的方法得到的产物,在式II化合物合成式III化合物中, 通过两阶段反应,中间不经过分离纯化,使用含式III化合物的粗品进行下一步反应,操作简便,更有利于提高产能和工业化生产。
(4)反应总收率高,对比现有技术中的其他路线,反应收率可以从25%左右提高到44%左右。
当然,实施本发明的任一方法必不一定需要同时达到以上所述的所有优点。
为使本发明的目的、技术方案、及优点更加清楚明白,以下通过具体实施例,对本发明进一步详细说明。显然,所描述的实施例仅仅是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有作出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。
在本发明的一个具体实施方式中:Lesinurad的制备方法可用反应方程式表示如下:
下面通过实施例的方式进一步说明本发明,但并不因此将本发明限制在所述的实施例范围之中。
实施例1:4-(4-环丙基萘)-1,2,4-三氮唑的制备
在三口瓶中,加入4-环丙基-1-萘胺(化合物1 20.00g,110.00mmol),二甲酰肼(29.06g,330.00mmol)以及吡啶(10V,200.00ml,),在室温下,缓慢滴加三甲基氯硅烷(59.75g,550.00mmol),反应随后升温回流2小时。LC确认反应结束后,过滤除去不溶性固体盐,滤液浓缩至干,所得残余物加乙酸乙酯溶解,有机相用水洗涤两次,干燥有机相,减压浓缩至约30ml,向浓缩液加甲基叔丁基醚90ml,所得悬浮液打浆搅拌1小时,抽滤得化合物2(纯度:98%),产率(70%)。
1H NMR(400MHz,CDCl
3)δ8.56(d,J=8.4Hz,1H),8.41(s,2H),7.70-7.66(m,1H),7.60-7.56(m,1H),7.44(d,J=8.4Hz,1H),7.38(d,7.6Hz,1H),7.36(d,7.6Hz,1H),2.44-2.40(m,1H),1.20-1.15(m,2H),0.86-0.82(m,2H);MS(ESI)m/z 236.11([M+H]
+)。
实施例2:4-(4-环丙基萘)-1,2,4-三氮唑的制备
在三口瓶中,加入4-环丙基-1-萘胺(化合物1 9.16g,50.00mmol),二甲酰肼(14.53g,165.00mmol)、甲苯(10V,91.60ml)以及吡啶(15.82g,200.00mmol),在室温下,缓慢滴加三甲基氯硅烷(29.87g,275.00mmol),反应随后升温回流2小时。LC确认反应结束后,过滤除去不溶性固体盐,滤液浓缩至干,所得残余物加乙酸乙酯溶解,有机相用水洗涤两次,干燥有机相,减压浓缩至约15ml,向浓缩液加甲基叔丁基醚45ml,所得悬浮液打浆搅拌1小时,抽滤得化合物2(纯度:98.2%),产率(78%)。
实施例3:4-(4-环丙基萘)-1,2,4-三氮唑的制备
在三口瓶中,加入4-环丙基-1-萘胺(化合物1 9.16g,50.00mmol),二甲酰肼(14.53g,165.00mmol)、乙腈(10V,91.6ml)以及三乙胺(20.24g,200mmol),在室温下,缓慢滴加三甲基溴硅烷(29.87g,275mmol),反应随后升温回流2 小时。LC确认反应结束后,过滤除去不溶性固体盐,滤液浓缩至干,所得残余物加乙酸乙酯溶解,有机相用水洗涤两次,干燥有机相,减压浓缩至约15ml,向浓缩液加甲基叔丁基醚45ml,所得悬浮液打浆搅拌1小时,抽滤得化合物2(纯度:98.0%),产率(77%)。
实施例4:4-(4-环丙基萘)-3,5-二溴-1,2,4-三氮唑的制备
在三口瓶中,加入4-(4-环丙基萘)-1,2,4-三氮唑(化合物2 11.50g,48.91mmol),四氢呋喃(6V,69.00ml),在室温下,分批加入N-溴代丁二酰亚胺(34.96g,122.28mmol)。反应随后在40℃下搅拌2小时。LC确认反应结束后。乙酸乙酯稀释反应液,有机相分别用30%硫代硫酸钠以及饱和碳酸氢钠溶液洗涤两次,干燥浓缩。残余物加甲基叔丁基醚40ml,悬浮液搅拌打浆1小时,抽滤,滤饼用甲基叔丁基醚10ml洗涤两次,得化合物3(纯度:99%),产率(85%)。
1H NMR(400MHz,CDCl
3)δ8.58(d,J=8.4Hz,1H),7.71-7.67(m,1H),7.62-7.58(m,1H),7.41(d,7.6Hz,1H),7.35(d,7.6Hz,1H),7.18(d,J=8.4Hz,1H),2.47-2.44(m,1H),1.21-1.18(m,2H),0.92-0.88(m,2H);MS(ESI)m/z391.93([M+H]
+)。
实施例5:4-(4-环丙基萘)-3,5-二溴-1,2,4-三氮唑的制备
在三口瓶中,加入4-(4-环丙基萘)-1,2,4-三氮唑(化合物2 11.50g,48.91mmol),二氯甲烷(6V,69.00ml),在室温下,分批加入液溴(34.96g,122.28mmol)。反应随后在40℃下搅拌2小时。LC确认反应结束后。乙酸乙酯稀释反应液,有机相分别用30%硫代硫酸钠以及饱和碳酸氢钠溶液洗涤两次,干燥浓缩。残余物加甲基叔丁基醚40ml,悬浮液搅拌打浆1小时,抽滤,滤饼用甲基叔丁基醚10ml洗涤两次,得化合物3(纯度:98%),产率(83%)。 MS(ESI)m/z 391.93([M+H]+)。
实施例6:4-(4-环丙基萘)-3,5-二溴-1,2,4-三氮唑的制备
在三口瓶中,加入4-(4-环丙基萘)-1,2,4-三氮唑(化合物2 11.50g,,48.91mmol),四氢呋喃(6V,69.00ml),在室温下,分批加入二溴海因(34.96g,122.28mmol)。反应随后在40℃下搅拌2小时。LC确认反应结束后。乙酸乙酯稀释反应液,有机相分别用30%硫代硫酸钠以及饱和碳酸氢钠溶液洗涤两次,干燥浓缩。残余物加甲基叔丁基醚40ml,悬浮液搅拌打浆1小时,抽滤,滤饼用甲基叔丁基醚10ml洗涤两次,得化合物3(纯度:98%),产率(82%)。MS(ESI)m/z 391.93([M+H]+)。
实施例7A:4-(4-环丙基萘)-3-硫代乙酸甲酯-5-溴-1,2,4-三氮唑的制备
在三口瓶中,加入4-(4-环丙基萘)-3,5-二溴-1,2,4-三氮唑(化合物3 4.00g,10.18mmol),N,N-二甲基甲酰胺(10V,40.00ml),在室温下,依次加入碳酸钾(2.10g,15.26mmol)和巯基乙酸甲酯(1.62g,15.26mmol)。反应室温搅拌1小时,LC检测原料反应完全。加乙酸乙酯稀释反应液,有机相用0.5N盐酸溶液洗涤一次,再用水洗涤3次,干燥浓缩后得4的粗品,过硅胶柱分离制备得化合物4(纯度:90%),收率(50%)
1H NMR(400MHz,CDCl
3)δ8.55(d,J=8.4Hz,1H),7.68-7.64(m,1H),7.60-7.56(m,1H),7.36(s,2H),7.26(d,J=8.4Hz,1H),4.09(d,J=16.4Hz,1H),4.03(d,J=16.4Hz,1H),3.72(s,3H),2.45-2.41(m,1H),1.19-1.15(m,2H),0.90-0.86(m,2H);MS(ESI)m/z 418.01([M+H]
+)。
实施例7B:4-(4-环丙基萘)-3-硫代乙酸甲酯-5-溴-1,2,4-三氮唑的制备
在三口瓶中,加入4-(4-环丙基萘)-3,5-二溴-1,2,4-三氮唑(化合物3 4.64g,11.80mmol),N,N-二甲基甲酰胺(10V,46.40ml),在室温下,依次加入碳酸钾(2.45g,17.71mmol)和巯基乙酸甲酯(1.88g,17.71mmol)。反应室温搅拌1小时,LC检测原料反应完全。此时向反应体系继续依次补加碳酸钾(1.79g,12.98mmol)和氯乙酸甲酯(1.41g,12.98mmol),反应室温下继续搅拌1小时。反应结束后,加乙酸乙酯稀释反应液,有机相用0.5N盐酸溶液洗涤一次,再用水洗涤3次,干燥浓缩得化合物4的粗品,不纯化直接用于下步反应。
实施例8:4-(4-环丙基萘)-3-硫代乙酸甲酯-5-溴-1,2,4-三氮唑的制备
在三口瓶中,加入4-(4-环丙基萘)-3,5-二溴-1,2,4-三氮唑(化合物3 4.64g,11.80mmol),乙腈(10V,46.4ml),在室温下,依次加入三乙胺(1.79g,17.71mmol)和巯基乙酸甲酯(1.88g,17.71mmol)。反应室温搅拌1小时,LC检测原料反应完全。此时向反应体系继续依次补加碳酸钠(1.37g,12.98mmol)和氯乙酸甲酯(1.41g,12.98mmol),反应室温下继续搅拌1小时。反应结束后,加乙酸乙酯稀释反应液,有机相用0.5N盐酸溶液洗涤一次,再用水洗涤3次,干燥浓缩得化合物4的粗品,不纯化直接用于下步反应。
实施例9:4-(4-环丙基萘)-3-硫代乙酸甲酯-5-溴-1,2,4-三氮唑的制备
在三口瓶中,加入4-(4-环丙基萘)-3,5-二溴-1,2,4-三氮唑(化合物3 4.64g,11.80mmol),N-甲基吡咯烷酮(10V,46.40ml),在室温下,依次加入碳酸钾(2.45g,17.71mmol)和巯基乙酸甲酯(1.88g,17.71mmol)。反应室温搅拌1小时,LC检测原料反应完全。此时向反应体系继续依次补加碳酸钾(1.79g,12.98mmol)和氯乙酸甲酯(1.41g,12.98mmol),反应室温下继续搅拌1小时。反应结束后,加乙酸乙酯稀释反应液,有机相用0.5N盐酸溶液洗涤一次,再用水洗涤3次,干燥浓缩得化合物4的粗品,不纯化直接用于 下步反应。
实施例10:4-(4-环丙基萘)-3-硫代乙酸乙酯-5-溴-1,2,4-三氮唑的制备
在三口瓶中,加入4-(4-环丙基萘)-3,5-二溴-1,2,4-三氮唑(化合物3 4.64g,11.80mmol),N,N-二甲基甲酰胺(10V,46.40ml),在室温下,依次加入碳酸钾(2.45g,17.71mmol)和巯基乙酸乙酯(2.13g,17.71mmol)。反应室温搅拌1小时,LC检测原料反应完全。此时向反应体系继续依次补加碳酸钾(1.79g,12.98mmol)和氯乙酸乙酯(1.59g,12.98mmol),反应室温下继续搅拌1小时。反应结束后,加乙酸乙酯稀释反应液,有机相用0.5N盐酸溶液洗涤一次,再用水洗涤3次,干燥浓缩得化合物19的粗品,不纯化直接用于下步反应(纯度89%,收率79%);
1H NMR(400MHz,CDCl
3)δ8.55(d,J=8.4Hz,1H),7.68-7.64(m,1H),7.60-7.56(m,1H),7.36(s,2H),7.26(d,J=8.4Hz,1H),4.09(d,J=16.4Hz,1H),4.03(d,J=16.4Hz,1H),3.72(s,3H),2.45-2.41(m,1H),1.33-1.27(t,3H),1.19-1.15(m,2H),0.90-0.86(m,2H);MS(ESI)m/z 432.03([M+H]
+)。
实施例11:Lesinurad的制备
在三口瓶中,加入4-(4-环丙基萘)-3-硫代乙酸甲酯-5-溴-1,2,4-三氮唑(上 一步没纯化的化合物4 4.93g,11.80mmol),四氢呋喃(10V,49.30ml),在室温下,向其中缓慢滴加1N氢氧化钠溶液(23.60ml,23.60mmol),反应在室温搅拌2小时。LC检测反应结束后,加水稀释反应液,水相用乙酸乙酯洗涤两次后,加1N盐酸溶液调至酸性后,再用乙酸乙酯萃取两次。所得有机相,干燥浓缩至干得化合物6的白色固体(纯度:98%),两步产率(75%)。
1H NMR(400MHz,CDCl
3)δ8.57(d,J=8.4Hz,1H),8.26(bs,1H),7.70-7.66(m,1H),7.62-7.58(m,1H),7.38(s,2H),7.23(d,J=8.4Hz,1H),4.03(d,J=15.6Hz,1H),3.96(d,J=15.6Hz,1H),2.47-2.43(m,1H),1.22-1.17(m,2H),0.91-0.87(m,2H);MS(ESI)m/z 404.00([M+H]
+)。
以上所述仅为本发明的较佳实施例而已,并不用以限制本发明,凡在本发明的精神和原则之内,所做的任何修改、等同替换、改进等,均应包含在本发明保护的范围之内。
Claims (10)
- 一种通式III的Lesinurad中间体化合物的制备方法,其特征在于,该方法包括以下反应步骤:1)将式II化合物与R 3-SH在第一溶剂和第一碱存在下发生取代反应,生成含有式III化合物和式IV化合物的混合物;2)在得到的混合物中加第二碱及R 3X进行反应,得到式III化合物;其中,R代表环丙烷基、卤素、三氟甲磺酸酯基、甲磺酸酯基或对甲苯磺酸酯基;优选地,R代表环丙烷基;R 3代表-COCH 3、苄基或-CH 2R 4,其中R 4代表乙酸甲酯基、乙酸乙酯基、-C(O)OC 2H 5、-C(O)OCH 3、-CN、-CH 2OH或被选自C1~C6烷基、卤素中的一种或多种取代的苯基;X代表卤素。
- 根据权利要求1所述的制备方法,其特征在于,所述的第一溶剂选自N,N-二甲基甲酰胺、N-甲基吡咯烷酮或乙腈中的一种或其任意组合;所述的步骤1)和步骤2)中的第一碱、第二碱分别选自1,8-二氮杂二环十一碳-7-烯、二异丙基乙基胺、三乙胺、碳酸钾或碳酸钠中的一种或其任意组合。
- 根据权利要求1或2所述的制备方法,其特征在于,所述步骤1)得到的混合物不纯化直接进行下一步反应,转化成式III化合物。
- 根据权利要5所述的制备方法,其特征在于,所述的溴化反应采用的溴化试剂选自液溴、溴水、N-溴代丁二酰亚胺、二溴海因、苯基三甲基三溴化铵、5,5-二溴巴比妥酸或二溴异氰尿酸中的一种或其任意组合;所述的第二溶剂选自四氢呋喃、2-甲基四氢呋喃、二氯甲烷或乙腈中的一种或其任意组合。
- 根据权利要求7所述的制备方法,其特征在于,所述的第三溶剂选自吡啶、乙腈或甲苯中的一种或其任意组合;所述的第三碱选自吡啶、三乙胺或者二异丙基乙基胺中的一种或其任意组合;所述的三甲基卤硅烷选自三甲基氯硅烷、三甲基溴硅烷或三甲基碘硅烷中的一种或其任意组合。
- 根据权利要求9所述的制备方法,其特征在于,所述步骤2)得到的化合物4不纯化直接进行下一步反应转化成lesinurad。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/491,444 US20200062720A1 (en) | 2017-05-17 | 2018-07-11 | Novel preparation method for anti-gout drug lesinurad, and key intermediate thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710346180.2A CN108947919B (zh) | 2017-05-17 | 2017-05-17 | 一种抗痛风药Lesinurad的新型制备方法及其关键中间体 |
CN201710346180.2 | 2017-05-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2018210354A1 true WO2018210354A1 (zh) | 2018-11-22 |
Family
ID=64273407
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2018/095269 WO2018210354A1 (zh) | 2017-05-17 | 2018-07-11 | 一种抗痛风药Lesinurad的新型制备方法及其关键中间体 |
Country Status (3)
Country | Link |
---|---|
US (1) | US20200062720A1 (zh) |
CN (1) | CN108947919B (zh) |
WO (1) | WO2018210354A1 (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111320588B (zh) * | 2018-12-14 | 2024-02-09 | 上海奥博生物医药股份有限公司 | 一种纯化Lesinurad的方法 |
CN112110866A (zh) * | 2019-06-20 | 2020-12-22 | 北京万全德众医药生物技术有限公司 | 一种雷西纳德的制备方法 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006026356A2 (en) | 2004-08-25 | 2006-03-09 | Ardea Biosciences, Inc. | S-TRIAZOLYL α-MERCAPTOACETANILDES AS INHIBITORS OF HIV REVERSE TRANSCRIPTASE |
CN101918377A (zh) * | 2007-11-27 | 2010-12-15 | 亚德生化公司 | 新颖化合物和组合物以及使用方法 |
CN102040546A (zh) | 2009-10-10 | 2011-05-04 | 台州市华南医化有限公司 | 一种4-环丙基-1-异硫氰基萘的制备方法及中间体4-环丙基-1-萘甲醛肟/卤化物 |
WO2014008295A1 (en) | 2012-07-03 | 2014-01-09 | Ardea Biosciences, Inc. | Manufacture of 2- (5- bromo-4 (-cyclopropylnaphthalen-1-yl) -4h-1,2,4-triazol-3-ylthio) acetic acid |
CN103524440A (zh) | 2013-10-15 | 2014-01-22 | 苏州鹏旭医药科技有限公司 | 痛风治疗药Lesinurad的制备方法及Lesinurad中间体 |
CN106478531A (zh) * | 2015-08-25 | 2017-03-08 | 南京华威医药科技开发有限公司 | 2-(5-溴-4-(4-环丙基萘-1-基)-4h-1,2,4-三唑-3-基硫基)乙酸中间体 |
-
2017
- 2017-05-17 CN CN201710346180.2A patent/CN108947919B/zh active Active
-
2018
- 2018-07-11 US US16/491,444 patent/US20200062720A1/en not_active Abandoned
- 2018-07-11 WO PCT/CN2018/095269 patent/WO2018210354A1/zh active Application Filing
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006026356A2 (en) | 2004-08-25 | 2006-03-09 | Ardea Biosciences, Inc. | S-TRIAZOLYL α-MERCAPTOACETANILDES AS INHIBITORS OF HIV REVERSE TRANSCRIPTASE |
CN101918377A (zh) * | 2007-11-27 | 2010-12-15 | 亚德生化公司 | 新颖化合物和组合物以及使用方法 |
CN102040546A (zh) | 2009-10-10 | 2011-05-04 | 台州市华南医化有限公司 | 一种4-环丙基-1-异硫氰基萘的制备方法及中间体4-环丙基-1-萘甲醛肟/卤化物 |
WO2014008295A1 (en) | 2012-07-03 | 2014-01-09 | Ardea Biosciences, Inc. | Manufacture of 2- (5- bromo-4 (-cyclopropylnaphthalen-1-yl) -4h-1,2,4-triazol-3-ylthio) acetic acid |
CN103524440A (zh) | 2013-10-15 | 2014-01-22 | 苏州鹏旭医药科技有限公司 | 痛风治疗药Lesinurad的制备方法及Lesinurad中间体 |
CN106478531A (zh) * | 2015-08-25 | 2017-03-08 | 南京华威医药科技开发有限公司 | 2-(5-溴-4-(4-环丙基萘-1-基)-4h-1,2,4-三唑-3-基硫基)乙酸中间体 |
Also Published As
Publication number | Publication date |
---|---|
US20200062720A1 (en) | 2020-02-27 |
CN108947919B (zh) | 2023-05-02 |
CN108947919A (zh) | 2018-12-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2583920C (en) | Non-peptide bradykinin antagonists and pharmaceutical compositions therefrom | |
CN110590635A (zh) | 左乙拉西坦及其中间体的制备方法 | |
CN114805314A (zh) | 一种恩赛特韦的合成方法 | |
WO2018210354A1 (zh) | 一种抗痛风药Lesinurad的新型制备方法及其关键中间体 | |
CN111018678B (zh) | 一种高纯度3-苯氧基溴丙烷的制备方法 | |
EP2850064A1 (en) | Process for preparation of montelukast sodium | |
US8969547B2 (en) | Method for preparing fluticasone furoate | |
US10640465B2 (en) | Method for preparing phenylalanine compound | |
WO2016146049A1 (zh) | 一种咪达唑仑的工业制造方法 | |
CN111574463B (zh) | 一种利格列汀中间体化合物ⅳ | |
CN112645889A (zh) | 一种法匹拉韦的精制方法 | |
CN106748884B (zh) | 一种比卡鲁胺中间体的制备方法 | |
CN111320588B (zh) | 一种纯化Lesinurad的方法 | |
CN111039838B (zh) | 一种3-乙酰巯基-2-甲基丙酸的制备方法 | |
CN113121428B (zh) | 一种孟鲁司特钠衍生物的制备方法 | |
CN115286491B (zh) | 一种2-[2-(6-溴己氧基)乙氧基甲基]-1,3-二氯苯的制备方法 | |
KR100893756B1 (ko) | 몬테루카스트의 효율적 제조방법 | |
CN111662233B (zh) | 一种一步法合成4-氯-1h-咪唑-2-羧酸乙酯的方法 | |
CN107365299B (zh) | 一种达比加群酯的制备方法及其中间体 | |
US9133196B2 (en) | Process for the preparation of acebrophylline | |
RU2455301C2 (ru) | Способ получения n-(6-метил-2,4-диоксо-1,2,3,4-тетрагидро-5-пиримидинсульфон)-n′-изоникотиноилгидразида | |
JPH0812658A (ja) | シドノン類の製造法 | |
CN113024433A (zh) | 一种氨磺必利亚砜杂质的制备方法 | |
CN115232020A (zh) | 一种合成n,n-二乙基-2-羟基苯乙酰胺及其类似物的方法及其应用 | |
CN112028827A (zh) | 一种奈他地尔关键中间体的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18801541 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 18801541 Country of ref document: EP Kind code of ref document: A1 |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 18801541 Country of ref document: EP Kind code of ref document: A1 |